NeuroMetrix, Inc. Reports Total Revenues of $11.5 Million for the Second Quarter of 2007, a Decrease of 18% from the Second Quarter of 2006; Net Loss of $1.3 Million Incurred in the Second Quarter of 2007

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the design, development and sale of proprietary products used to help physicians diagnose neuropathies, or diseases of the nerves, and neurovascular diseases, announced today the financial results for the three month and six month periods ended June 30, 2007.